An Tuarascáil Eorpach um Dhrugaí 2026: Treochtaí agus Forbairtí: sonraí foinseacha
Sa chuach sonraí seo tá na táblaí sonraí foinseacha uile le haghaidh na Tuarascála Eorpaí um Dhrugaí 2026: Treochtaí agus Forbairtí. Úsáidtear na táblaí sonraí seo chun na léirshamhluithe sonraí agus táblaí eile sa tuarascáil a ghiniúint. Tá naisc chuig na táblaí sonraí foinseacha chun amharcléirithe sonraí a chruthú le haghaidh rannáin shonracha le fáil freisin ag bun gach leathanaigh, agus, i bhformhór na gcásanna, faoi bhun gach grafaice.
Nótaí:
- Tabhair faoi deara nach bhfuil sa tacar sonraí a chuirtear i láthair ar an leathanach seo ach fothacar beag de na sonraí a bhailítear trínár n‑eagraíochtaí comhpháirtíochta. Chun tuilleadh sonraí agus staitisticí a fháil, chomh maith le nótaí modheolaíochta mionsonraithe agus foláirimh, féach Feasachán Staidrimh 2026, a seoladh in éineacht leis an tuarascáil seo.
- Mura luaitear a mhalairt, tá na tacair shonraí go léir go hiomlán comhoiriúnach leis an gceadúnas Creative Commons Attribution 4.0 International (CC BY 4.0). Fágann sé seo go bhfuil tú saor chun ár gcuid sonraí agus staitisticí a athúsáid i do chuid oibre agus i do thaighde ar choinníoll go n‑aithnítear an fhoinse.
- Tá gach comhad i bhformáid CSV (luachanna camógdheighilte), ar formáid í a bhféadann an chuid is mó de bhogearraí scarbhileoige nó staitistiúla í a oscailt.
Nótaí modheolaíochta
Sonraí maidir le leitheadúlacht úsáide drugaí
- Tá na sonraí leitheadúlachta a chuirtear i láthair anseo bunaithe ar shuirbhéanna ar an bpobal i gcoitinne arna gcur faoi bhráid EUDA ag pointí fócasacha náisiúnta Reitox. Chun teacht ar na sonraí is déanaí agus ar fhaisnéis mhionsonraithe mhodheolaíoch, féach Feasachán Staidrimh 2026: Leitheadúlacht úsáide druga.
- Na grafaicí ina léirítear na sonraí is déanaí ar leibhéal na tíre, tá siad bunaithe ar staidéir a rinneadh idir sa tréimhse ó 2015 go 2024.
- Cumhdaítear leis an gcoincheap ‘amfataimíní’ amfataimín agus meitiolamfataimín araon. Tá na sonraí leitheadúlachta a chuirtear i láthair anseo bunaithe ar shuirbhéanna ar an bpobal i gcoitinne arna gcur faoi bhráid EUDA ag pointí fócasacha náisiúnta.
- Meastacháin ar leitheadúlacht cannabais don daonra i gcoitinne: is iad na haoisraonta 18-64 agus 18-34 don Ghearmáin, don Ghréig, don Fhrainc, don Iodáil agus don Ungáir; 16-64 agus 16-34 don Danmhairg, don Eastóin, don tSualainn agus don Iorua; 18-65 agus 18-34 do Mhálta.
- Meastacháin ar leitheadúlacht cócaoin: is iad na haoisraonta 18-64 agus 18-34 don Ghearmáin, don Ghréig, don Fhrainc, don Iodáil agus don Ungáir; 16-64 agus 16-34 don Danmhairg, don Eastóin agus don Iorua; 18-65 agus 18-34 do Mhálta; 17-34 don tSualainn.
- Meastacháin ar leitheadúlacht amfataimíní don daonra i gcoitinne: is iad na haoisraonta 18-64 agus 18-34 don Ghearmáin, don Ghréig, don Fhrainc, don Iodáil agus don Ungáir; 16-64 agus 16-34 don Danmhairg, don Eastóin agus don Iorua; 18-34 do Mhálta; 17-34 don tSualainn.
- Meastacháin ar leitheadúlacht MDMA / eacstaise don daonra i gcoitinne: is iad na haoisraonta 18-64 agus 18-34 don Ghearmáin, don Ghréig, don Fhrainc, don Iodáil agus don Ungáir; 16-64 agus 16-34 don Danmhairg, don Eastóin agus don Iorua; 18-65 agus 18-34 do Mhálta; 17-34 don tSualainn.
Sonraí faoin éileamh ar chóireáil
- Seachas na treochtaí, baineann sonraí le gach iontrálaí cóireála a bhfuil an tsubstaint mar phríomhdhruga acu – 2024 nó an bhliain is déanaí atá ar fáil.
- Tá treochtaí a bhaineann le hiontrálaithe céaduaire bunaithe ar fhaisnéis ó 26 thír. Ní áirítear san anailís treochtaí ach na tíortha a bhfuil sonraí le fáil ina leith ar feadh ar a laghad 6 de na 7 mbliana. Déantar luachanna atá in easnamh a idirshuí ó bhlianta cóngaracha. Mar gheall ar chur isteach ar sheirbhísí de thairbhe COVID-19, ba cheart sonraí do 2020, 2021 agus 2022 a léirmhíniú go cúramach. Rinneadh sonraí a bhí ar iarraidh a iontráil go barúlach le luachanna ón mbliain roimhe sin i gcás na Spáinne agus na Fraince (2024) agus na Gearmáine (2019). Sa Ghearmáin, déantar difear do na treochtaí toisc gur fíorbheagán duine a tharchuirtear ón gcóras ceartais choiriúil a thuilleadh, i ndiaidh an athraithe ar an reachtaíocht i mí Feabhra 2024.
- Bealaí riaracháin, hearóin: Áirítear le ‘bealaí eile’ ithe/ól, bolú agus príomhbhealaí neamhshonraithe tabhartha. Tá treochtaí bunaithe ar fhaisnéis ó 19 mBallstát den Aontas a chuireann sonraí ar fáil thar an tréimhse; ní áirítear ach na Ballstáit sin a bhfuil sonraí acu le haghaidh 9 mbliana ar a laghad as an 11 bhliain atá i gceist. Déantar luachanna atá in easnamh a idirshuí ó bhlianta cóngaracha. Mar gheall ar chur isteach ar sheirbhísí de thairbhe COVID-19, ba cheart sonraí do 2020, 2021 agus 2022 a léirmhíniú go cúramach.
Sonraí soláthair agus margaí
- Léirítear leis na treochtaí innéacsaithe a chuirtear i láthair athruithe coibhneasta ar urghabhálacha drugaí thar thréimhse 10 mbliana, ach ní thugtar aon léiriú iontu ar na méideanna iarbhír.
- Rinneadh táibléid MDMA a thiontú go maischoibhéisí trí ghlacadh le mais de 0.25 gram MDMA in aghaidh an táibléid.
- Tagraíonn AE+2 do Bhallstáit AE móide an Iorua agus an Tuirc.
- Praghas agus neart: meánluachanna náisiúnta – raon íosta, uasta agus idircheathairíle. Tá táscaire éagsúil luaite le tíortha.
Sonraí fuíolluisce
- Tugtar meánmhéideanna laethúla na sprice i milleagraim in aghaidh gach 1 000 daonra. I bhformhór na gcathracha, rinneadh sampláil thar sheachtain idir mí an Mhárta agus mí na Bealtaine 2025.
- Agus earráidí staidrimh á gcur san áireamh, meastar go bhfuil luachanna atá difriúil faoi bhun 10 % ón luach roimhe sin cobhsaí i dtáblaí ina léirítear athruithe idir 2024 agus 2025.
- Foinse: Croíghrúpa na hEorpa um Anailís Séarachais (SCORE)
- Chun an tacar iomlán sonraí agus an anailís iomlán a fháil, féach Anailís ar fhuíolluisce agus drugaí – staidéar ilchathrach Eorpach.
Sonraí Euro-DEN Plus
- I gcás sonraí na n-athruithe bliain ar bhliain, meastar gur luachanna cobhsaí iad luachanna a bhfuil difríocht níos lú ná 10% eatarthu agus an luach roimhe sin. Ní dhéantar ionadaíocht ach ar ionaid ina dtuairiscítear 20 cur i láthair ar a laghad do gach bliain.
- Sa Bhratasláiv, i mBúcairist, in Gdansk agus i Ríge, bhí 10 gcás nó níos lú de chásanna a bhain le cócaon ann in 2024, rud a chuireann teorainn leis an inchomparáideacht idir na blianta. Chun teacht ar na sonraí is déanaí agus ar fhaisnéis mhionsonraithe mhodheolaíoch, féach: Taiscéalaí sonraí Euro-DEN.
Sonraí maidir le seiceáil drugaí
- An Líonra Faisnéise Drugaí Tras-Eorpach (TEDI). Sonraí ó 11 sheirbhís Eorpacha um sheiceáil drugaí i 7 mBallstát de chuid an Aontais, 2024 agus 2025.
Sonraí faoi bhásanna de bharr drugaí
- Cion de na básanna ina luaitear ópóidigh: sonraí ó chláir mhortlaíochta speisialta. Cuimsítear tíortha a bhfuil 70 cás ar a laghad tuairiscithe iontu. Tá na tíortha ordaithe in ord íslitheach de réir an chionáin de chásanna a bhaineann le hearóin. I roinnt tíortha, tá na sonraí maidir leis na hópóidigh bheachta atá i gceist ar iarraidh.
- Sonraí treochtaí: níl sonraí inchomparáide don Ghearmáin ar fáil roimh 2021. Le haghaidh léirshamhlú an treochta, líonadh na blianta níos luaithe leis an gcéad phointe sonraí a bhí ar fáil. Mar sin féin, de réir an tsainmhínithe náisiúnta a úsáideadh ag an am, tháinig méadú ar líon na mbásanna de bharr drugaí sa Ghearmáin suas go dtí 2020. Níl sonraí ar fáil do roinnt tíortha le haghaidh 2023 nó 2024. Sna cásanna sin, baineadh úsáid as na sonraí is déanaí a bhí ar fáil in ionad na luachanna a bhí in easnamh (2022 don Bheilg, d’Éirinn, don Ghréig; 2023 don Spáinn, don Fhrainc, don Pholainn, don Phortaingéil).
Sonraí maidir le laghdú díobhála
- Dáileadh snáthaidí agus steallairí agus cumhdach cóireáil le hagónaithe ópóideacha i ndáil le spriocanna 2025 na hEagraíochta Domhanda Sláinte: tá an cumhdach bunaithe ar na meastacháin náisiúnta is déanaí maidir le húsáid drugaí insteallta agus úsáid ópóideach ardriosca, meaitseáilte le sonraí gníomhaíochta um laghdú díobhála (laistigh de 2 bhliain ar a mhéad). Díorthaítear an meastachán maidir le cumhdach na cóireála le hagónaithe ópóideacha don Bheilg ó staidéar fonáisiúnta a rinneadh in 2019.
- Nalocsón lena úsáid sa bhaile: Baineann na sonraí le Ballstáit an Aontais, leis an Iorua agus leis an Tuirc in 2024. Sa Ghréig in 2023, eisíodh dlí maidir le nalocsón a thabhairt abhaile; in 2025, eisíodh foraithne aireachta lenar ceadaíodh an clár a chur chun feidhme.
- Table EDR26-GPS-1. Prevalence of drug use in Europe, based on most recent general population surveys (2024 or most recent year)
- Table EDR26-GPS-2. Prevalence of drug use in Europe, trends
- Table EDR26-WW-1. Mean weekly measurements by targeted substance from wastewater analysis in selected European cities in 2025
- Table EDR26-TDI-1. Treatment demand indicator (TDI) source data, client characteristics, 2024 or most recent year. Percentages except where otherwise stated
- Table EDR26-Sup-1. Number of reported drug seizures, breakdown by drug, 2024
- Table EDR26-Sup-2. Drug seizures in the European Union — number of drug seizures, indexed trends (2014 = 100)
- Table EDR26-Sup-3. Drug seizures in the European Union — quantity of drugs seized, indexed trends (2014 = 100)
- Table EDR26-Sup-4. Drug seizures in the European Union — number of seizures in 2024
- Table EDR26-Sup-5. Drug seizures in the European Union — quantity seized in 2024 (tonnes)
- Table EDR26-Sup-6. Drug law offences — possession/use offences, indexed trends (2014 = 100)
- Table EDR26-Sup-7. Drug law offences — supply offences, indexed trends (2014 = 100)
- Table EDR26-Sup-8. Drug law offences — number of offences, supply and use/possession, 2024
- Table EDR26-Sup-9. Quantity of precursors (EU) and key non-scheduled chemicals seized in the European Union (2012-2024)
- Table EDR26-Sup-10. Quantities of precursors and key non-scheduled chemicals seized in the European Union in 2024 (kilograms), by their association with drug production
- Table EDR26-Sup-11. Quantities of key precursor chemicals seized in the European Union in 2024 (litres), by association with drug production
- Table EDR26-Sup-12. Summary of seizures of EU scheduled precursors and non-scheduled chemicals used for selected drugs produced in the European Union, 2024
- Table EDR26-Cannabis-3. Trends in first-time entrants, cannabis, selected countries
- Table EDR26-Cannabis-4. Cannabis markets seizures source data, 2024 or most recent year
- Table EDR26-Cannabis-5. Trends in the number of cannabis seizures and quantity of illicit drugs seized (x 1000)
- Table EDR26-Cannabis-6. Trends in the quantities of cannabis seizures and quantity of illicit drugs seized (tonnes)
- Table EDR26-Cannabis-7. Price, potency data for cannabis, 2024 or most recent year
- Table EDR26-Cannabis-8. Price and purity/potency indexed trends
- Table EDR26-Cocaine-3. Trends in first-time entrants, cocaine, selected countries
- Table EDR26-Cocaine-4. Cocaine markets seizures source data
- Table EDR26-Cocaine-5. Trends in the number of cocaine seizures and quantity of illicit drugs seized (x 1000)
- Table EDR26-Cocaine-6. Trends in the quantities of cocaine seizures and quantity of illicit drugs seized (tonnes)
- Table EDR26-Cocaine-7. Price, potency data for cocaine, 2024 or most recent year
- Table EDR26-Cocaine-10. Price and purity/potency indexed trends, cocaine
- Table EDR26-Cocaine-9. Trends in the numbers of cocaine-related presentations in Euro-DEN Plus sentinel hospitals 2023 to 2024
- Table EDR26-Cocaine-11. Polysubstance toxicity in drug-related deaths cases with cocaine involved
- Table EDR26-Stimulants-1. Amphetamine and methamphetamine entrants as a share of all first-time treatment entrants
- Table EDR26-Stimulants-2. Trends in all entrants for synthetic cathinone users
- Table EDR26- Stimulants-3. Synthetic stimulants seizures source data, 2024 or most recent year
- Table EDR26-Stimulants-4. Synthetic stimulants market price and purity data, 2024 or most recent year
- Table EDR26-Stimulants-7. Trends in the quantities of synthetic stimulants seized, tonnes 2014-2024
- Table EDR26-Stimulants-6. Trends in the number of synthetic stimulants seizures 2014-2024
- Table EDR26-Stimulants-5. Synthetic stimulants retail market price and purity data indexed trends (2014=100)
- Table EDR26-MDMA-2. MDMA markets seizures source data, 2024 or most recent year
- Table EDR26-MDMA-5. Trends in the number of MDMA seizures
- Table EDR26-MDMA-4. Trends in the quantity of MDMA seized: tablets
- Table EDR26-MDMA-5. Trends in the quantity of MDMA seized: powder (tonnes)
- Table EDR26-MDMA-6. MDMA price and purity or content data, 2024 or most recent year
- Table EDR26-MDMA-7. Price and MDMA content indexed trends
- Table EDR26-MDMA-8. MDMA purity or content of samples submitted to drug checking services (percent), 2024
- Table EDR26-MDMA-9. Psychoactive adulterants detected in samples sold as MDMA to users and tested in 12 European drug checking services, 2024
- Table EDR26-Heroin-1. Age distribution of all clients entering treatment with heroin as their primary drug, 2010 and 2024 (%)
- Table EDR26-Heroin-2. Age distribution of never previously treated clients entering treatment with heroin as their primary drug, 2010 and 2024 (%)
- Table EDR26-Heroin-3. Trends in first-time heroin treatment entrants
- Table EDR26-Heroin-4. Trends in the main route of administration of clients entering treatment with heroin as primary drug, by treatment status (%)
- Table EDR26-Heroin-5. Heroin markets seizures source data
- Table EDR26-Heroin-6. Trends in the number of heroin seizures (x 1000)
- Table EDR26-Heroin-7. Trends in the quantities of heroin seizures (tonnes)
- Table EDR26-Heroin-8. Price, potency data for heroin
- Table EDR26-Heroin-9. Price and purity/potency indexed trends, heroin
- Table EDR26-Heroin-10a. Proportion of the acute drug toxicity presentations with heroin involved in 2023
- Table EDR26-Heroin-10b.Trends in the proportion of the acute drug toxicity presentations with heroin involved in selected hospitals in Europe
- Table EDR26-Heroin-12. Other opioids: number of seizures and quantities seized, 2023
- Table EDR26-NPS-1. Number of new psychoactive substances reported for the first time to the EU Early Warning System, by category, 2005–2024
- Table EDR26-NPS-2. Number of new psychoactive substances reported each year following their first detection in the European Union, by category, 2005–2024
- Table EDR26-NPS-3a. Seizures of new psychoactive substances in the European Union: total number and total quantity of material seized, 2005–2024
- Table EDR26-NPS-3b. Seizures of new psychoactive substances in the European Union: total number of material seized, 2005–2024
- Table EDR26-NPS-4. Number of opioids reported for the first time to the EU Early Warning System, 2009–2024
- Table EDR26-NPS-5. Seizures of new psychoactive substances in the European Union: quantity seized, by substance, 2024
- Table EDR26-NPS-6. Notifications of new psychoactive substances under the terms of Regulation (EC) no 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) – 2024
- Table EDR24-Ketamine-1a. Seizures of ketamine powder in the European Union: total number, 2006–2024
- Table EDR26-Ketamine-1b. Seizures of ketamine powder in the European Union: total quantity, 2006-2024
- Table EDR26-Ketamine-2. Ketamine residues detected in wastewater in selected European cities: 2024
- Table EDR26-BZD-1. Number of formal notifications of benzodiazepines reported to the EU Early Warning System, 2011-25
- Table EDR26-Other-8a. Number of seizures and quantity seized of other drugs, European Union, 2024
- Table EDR26-Other-8b. Number of seizures and quantity seized of other drugs, European Union, Norway and Türkiye, 2024 or most recent year
- Table EDR26-Other-9. Proportion of all acute drug toxicity presentations related to GHB/GBL (percent), 2024
- Table EDR26-INJ-1a. Estimated number and prevalence of people who inject drugs, by country (latest available data for each country)
- Table EDR26-INJ-1b. Estimated prevalence (per 1000 people) of people who inject drugs, (latest available data for each country)
- Table EDR26-INJ-2. Trends in injecting among first-time treatment entrants with heroin, cocaine, amphetamine or methamphetamine as primary drug: percentage reporting injecting as main route of administration
- Table EDR26-INJ-3a. European Syringe Collection and Analysis Project Enterprise (ESCAPE) selected data for 2024
- Table EDR26-INJ-3b. ESCAPE project site location data
- Table EDR26-DRID-1. New HIV notifications linked to injecting drug use in the European Union, 2009 to 2024
- Table EDR26-DRID-2. Most-recent HIV outbreaks in Europe among people who inject drugs and the associated injected substance, 2014 to 2024
- Table EDR26-DRID-3. Number of sterile syringes distributed per person who inject drugs per year, 2024 or latest data
- Table EDR26-DRID-5a. New HIV cases attributable to injecting drug use, 2024 or most recent year
- Table EDR26-DRID-5b. New AIDS cases attributable to injecting drug use, 2024 or most recent year
- Table EDR26-DRID-5c. Trends in drug-related HIV: EU and selected countries (cases per million population)
- Table EDR26-DRID-5d. Countries with national data on HCV and HBV, 2024
- Table EDR26-DRID-6. Prevalence of active HCV infection among people who inject drugs, by country, 2024 or latest available data
- Table EDR26-DRID-7. Trends in HCV-RNA prevalence (%) among people who inject drugs: results from seroprevalence studies, 2013-2024
- Table EDR26-DRD-1. Characteristics of drug-induced deaths: numbers, 2024 or most recent year
- Table EDR26-DRD-1. Characteristics of drug-induced deaths: numbers, 2024 or most recent year
- Table EDR26-DRD-1a. Characteristics of drug-induced deaths: gender (percent), 2024 or most recent year
- Table EDR26-DRD-1b. Characteristics of drug-induced deaths: age (by gender), 2024 or most recent year
- Table EDR26-DRD-2. Age distribution of drug-induced deaths reported in the European Union, Norway and Türkiye in 2024 or the most recent year
- Table EDR26-DRD-3. Proportion of males among drug-induced deaths in the European Union, Norway and Türkiye in 2024, or most recent year (percent)
- Table EDR24-DRD-4. Drug-induced deaths in the European Union: age at death, 2024 or most recent available data (percent)
- Table EDR26-DRD-7. Proportion of drug-induced deaths cases with opioids mentioned, 2024 or most recent available data
- EDR26-DRD-5 Number of drug-induced deaths reported in the European Union in 2014 and 2024, or the most recent year, by age band
- Table EDR24-DRD-6. Trends in drug-induced deaths in the European Union, Norway and Türkiye
- Table EDR26-DRD-10. Opioids mentioned in drug-induced deaths, by substance
- Table EDR26-DRD-11. Number and rates per million population of drug-induced deaths reported in the European Union in 2014 and 2024, or the most recent year, by sex and age band
- Table EDR26-OAT-1. Coverage of opioid agonist treatment in 2024 or the most recent year and 2013/14 (Percent)
- Table EDR26-OAT-2. Clients in opioid agonist treatment
- Table EDR26-OAT-3 Number of European countries implementing opioid agonist treatment, up to 2025
- Table EDR26-HR-1. Number of European countries implementing harm reduction interventions, up to 2025
- Table EDR26-HR-2. Availability of take-home naloxone in Europe
- Table EDR26-HR-3. Needle and syringe distribution and opioid agonist treatment coverage in relation to WHO 2020 targets, 2023 or latest available estimate
- Table EDR26-HR-4. Location and number of drug consumption facilities throughout Europe 2025
- Table EDR26-HR-5. Availability of drug-related and other health and social care interventions targeting people who use drugs and are in prison, EU+2, 2024
- Table EDR26-Annex-table-1a. High-risk opioid use estimates for population aged 15–64 years, 2024 or most recent year
- Table EDR26-Annex-table-1b. Entrants into treatment during the year: opioids clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-1c. Entrants into treatment during the year: proportion of opioids clients with injection as main route of administration, 2024 or most recent year
- Table EDR26-Annex-table-1d. Number of clients in opioid agonist treatment, 2024 or most recent year
- Table EDR26-Annex-table-2a. Cocaine prevalence estimates among the general population and school students, 2024 or most recent year
- Table EDR26-Annex-table-2b. Entrants into treatment during the year - cocaine clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-2c. Entrants into treatment during the year: proportion of cocaine clients with injection as main route of administration, 2024 or most recent year
- Table EDR26-Annex-table-3a. Amphetamines prevalence estimates among the general population and school students, 2024 or most recent year
- Table EDR26-Annex-table-3b. Entrants into treatment during the year - amphetamines clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-3c. Entrants into treatment during the year: proportion of amphetamines clients with injection as main route of administration, 2024 or most recent year
- Table EDR26-Annex-table-4a. MDMA prevalence estimates among the general population and school students, 2024 or most recent year
- Table EDR26-Annex-table-4b. Entrants into treatment during the year - MDMA clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-5a. Cannabis prevalence estimates among the general population and school students, 2024 or most recent year
- Table EDR26-Annex-table-5b. Entrants into treatment during the year - cannabis clients as a proportion of treatment demands, 2024 or most recent year
- Table EDR26-Annex-table-6. Drug-induced deaths, HIV diagnoses, injecting drug use estimates, syringes distributed through specialised programmes, 2024 or most recent year
- Table EDR26-Annex-table-7. Seizures data, 2024 or most recent year
- Table EDR26-At-a-glance-1. Drug use in the EU in 2024, at a glance (amphetamines, cannabis, cocaine, MDMA)
- Table EDR26-At-a-glance-2. Heroin and other opioids in the EU in 2024, at a glance